Patents by Inventor Tina Møller Tagmose

Tina Møller Tagmose has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PROTEASE STABILIZED ACYLATED INSULIN ANALOGUES
    Publication number: 20150210747
    Abstract: Novel acylated insulin analogues exhibiting resistance towards proteases can, effectively, be administered pulmonary or orally. The insulin analogues contain B25H and A14E or A14H.
    Type: Application
    Filed: April 13, 2015
    Publication date: July 30, 2015
    Inventors: Peter Madsen, Thomas B. Kjeldsen, Thomas Hoeg-Jensen, Palle Jakobsen, Tina Moeller Tagmose, Tine Glendorf, Janos Tibor Kodra, Patrick William Garibay, Jacob Sten Petersen
  • PROTEASE STABILIZED ACYLATED INSULIN ANALOGUES
    Publication number: 20150210748
    Abstract: Novel acylated insulin analogues exhibiting resistance towards proteases can, effectively, be administered pulmonary or orally. The insulin analogues contain B25H and A14E or A14H.
    Type: Application
    Filed: April 14, 2015
    Publication date: July 30, 2015
    Inventors: Peter Madsen, Thomas B. Kjeldsen, Thomas Hoeg-Jensen, Palle Jakobsen, Tina Moeller Tagmose, Tine Glendorf, Janos Tibor Kodra, Patrick William Garibay, Jacob Sten Petersen
  • Protease stabilized, acylated insulin analogues
    Patent number: 9045560
    Abstract: Novel acylated insulin analogues exhibiting resistance towards proteases can, effectively, be administered pulmonary or orally. The insulin analogues contain B25H and A14E or A14H.
    Type: Grant
    Filed: August 22, 2013
    Date of Patent: June 2, 2015
    Assignee: NOVO NORDISK A/S
    Inventors: Peter Madsen, Thomas Boerglum Kjeldsen, Thomas Hoeg-Jensen, Palle Jakobsen, Tina Moeller Tagmose, Tine Glendorf, Jaanos Tibor Kodra, Patrick William Garibay, Jacob Sten Petersen
  • Protease stabilized, pegylated insulin analogues and uses thereof
    Patent number: 8987197
    Abstract: Novel PEGylated insulin analogs exhibiting resistance towards proteases can, effectively, be administered pulmonary or orally. The insulin analogs contain B25H and A14E or A14H. The PEGylation is at B29K.
    Type: Grant
    Filed: November 29, 2011
    Date of Patent: March 24, 2015
    Assignee: Novo Nordisk A/S
    Inventors: Peter Madsen, Thomas Hoeg-Jensen, Thomas Børglum Kjeldsen, Tina Møller Tagmose
  • NOVEL INSULIN DERIVATIVES
    Publication number: 20140349925
    Abstract: The present invention relates to insulin derivatives which are naturally occurring insulins or analogues thereof which have a side chain attached either to the ?-amino group of the N-terminal amino acid residue of the B chain or to the ?-amino group of a Lys residue present in the B chain of the parent insulin, the side chain being of the general formula: —W—X—Y—Z wherein W, X, Y and Z are as defined in the disclosure.
    Type: Application
    Filed: August 6, 2014
    Publication date: November 27, 2014
    Inventors: Ib Jonassen, Thomas Hoeg-Jensen, Svend Havelund, Ulla Ribel-Madsen, Tina Moeller Tagmose, Peter Madsen
  • Insulin derivatives
    Patent number: 8828923
    Abstract: The present invention relates to insulin derivatives which are naturally occurring insulins or analogues thereof which have a side chain attached either to the ?-amino group of the N-terminal amino acid residue of the B chain or to the ?-amino group of a Lys residue present in the B chain of the parent insulin, the side chain being of the general formula: —W—X—Y—Z wherein W, X, Y and Z are as defined in the disclosure.
    Type: Grant
    Filed: September 16, 2009
    Date of Patent: September 9, 2014
    Assignee: Novo Nordisk A/S
    Inventors: Ib Jonassen, Thomas Hoeg-Jensen, Svend Havelund, Ulla Ribel-Madsen, Tina Møller Tagmose, Peter Madsen
  • Multi-Substituted Insulins
    Publication number: 20140228285
    Abstract: The present invention regards an insulin derivative comprising at least 2 albumin binding moieties, wherein said albumin binding moieties comprise fatty diacid substitutions and a method for preparing such an insulin derivative by acylation and/or reductive alkylation. The present invention also concern a pharmaceutical comprising such an insulin derivative.
    Type: Application
    Filed: June 14, 2012
    Publication date: August 14, 2014
    Applicant: NOVO NORDISK A/S
    Inventors: Thomas Hoeg-Jensen, Peter Madsen, Jane Spetzler, Tina Moeller Tagmose
  • Method of acylating a peptide or protein
    Patent number: 8791236
    Abstract: A method for selectively acylating an amino group in a peptide or protein which has two or more reactive nucleophilic functional groups is described.
    Type: Grant
    Filed: January 28, 2014
    Date of Patent: July 29, 2014
    Assignee: Novo Nordisk A/S
    Inventors: Caspar Christensen, Rune Severinsen, Anders Klarskov Petersen, Steffen Kidal, Claus U. Jessen, Peter Madsen, Henrik Valore, Tina Moeller Tagmose, Jan Lindy Soerensen
  • Method of Acylating a Peptide or Protein
    Publication number: 20140142280
    Abstract: A method for selectively acylating an amino group in a peptide or protein which has two or more reactive nucleophilic functional groups is described.
    Type: Application
    Filed: January 28, 2014
    Publication date: May 22, 2014
    Applicant: Novo Nordisk A/S
    Inventors: Caspar Christensen, Rune Severinsen, Anders Klarskov Petersen, Steffen Kidal, Claus U. Jessen, Peter Madsen, Henrik Valore, Tina Moeller Tagmose, Jan Lindy Soerensen
  • Insulin derivatives
    Patent number: 8722620
    Abstract: The present invention is related to insulin derivatives having a side chain attached to an ?-amino group of a Lys residue present in the A-chain or to an ?-amino group of a Lys residue in the B-chain.
    Type: Grant
    Filed: February 27, 2007
    Date of Patent: May 13, 2014
    Assignee: Novo Nordisk A/S
    Inventors: Charlotte Harkjaer Fynbo, Ib Jonassen, Thomas Børglum Kjeldsen, Peter Madsen, Patrick William Garibay, Janos Tibor Kodra, Thomas Hoeg-Jensen, Tina Møller Tagmose
  • PEGylated, extended insulins
    Patent number: 8710001
    Abstract: PEGylated, extended insulins are insulins which, compared with human insulin, has one or more extensions extended from the A1, B1, A21 and/or B30 position(s), said extension(s) consist(s) of amino acid residue(s) and wherein a PEG moiety, via a linker, is attached to one or more of the amino acid residues in the extension(s). PEG is polyethyleneglycol. Such PEGylated, extended insulins have higher bioavailability and a longer time-action profile than regular insulin and are in particular suited for pulmonary administration and can, conveniently, be used to treat diabetes.
    Type: Grant
    Filed: September 2, 2011
    Date of Patent: April 29, 2014
    Assignee: Novo Nordisk A/S
    Inventors: Peter Madsen, Thomas Børglum Kjeldsen, Tina Møller Tagmose, Palle Jakobsen
  • Protease stabilized, acylated insulin analogues
    Patent number: 8691759
    Abstract: Novel acylated insulin analogues exhibiting resistance towards proteases can, effectively, be administered pulmonary or orally. The insulin analogues contain B25H and A14E or A14H.
    Type: Grant
    Filed: March 13, 2009
    Date of Patent: April 8, 2014
    Assignee: Novo Nordisk A/S
    Inventors: Peter Madsen, Thomas Boerglum Kjeldsen, Thomas Hoeg-Jensen, Palle Jakobsen, Tina Moeller Tagmose, Janos Tibor Kodra, Patrick William Garibay
  • PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES
    Publication number: 20140073564
    Abstract: Novel acylated insulin analogues exhibiting resistance towards proteases can, effectively, be administered pulmonary or orally. The insulin analogues contain B25H and A14E or A14H.
    Type: Application
    Filed: August 22, 2013
    Publication date: March 13, 2014
    Applicant: Novo Nordisk A/S
    Inventors: Peter Madsen, Thomas Boerglum Kjeldsen, Thomas Hoeg-Jensen, Palle Jakobsen, Tina Moeller Tagmose, Tine Glendorf, Jaanos Tibor Kodra, Patrick William Garibay, Jacob Sten Petersen
  • Method of acylating a peptide or protein
    Patent number: 8637647
    Abstract: A method has for selectively acylating an amino group in a peptide or protein which has two or more reactive nucleophilic functional groups is described.
    Type: Grant
    Filed: September 11, 2009
    Date of Patent: January 28, 2014
    Assignee: Novo Nordisk A/S
    Inventors: Caspar Christensen, Rune Severinsen, Anders Klarskov Petersen, Steffen Kidal, Claus U. Jessen, Peter Madsen, Henrik Valore, Tina Møller Tagmose, Jan Lindy Sørensen
  • FGF21 ANALOGUES AND DERIVATIVES
    Publication number: 20130252884
    Abstract: Novel analogues of Fibroblast Growth Factor 21 (FGF21), derivatives thereof having a modifying moiety covalently attached thereto, and pharmaceutical use of these analogues and derivatives, in particular, for the treatment of diabetes, dyslipidemia, obesity, cardiovascular diseases, metabolic syndrome, and/or Non Alcoholic Fatty Liver Disease (NAFLD) are described.
    Type: Application
    Filed: June 6, 2011
    Publication date: September 26, 2013
    Applicant: NOVO NORDISK A/S
    Inventors: Patrick William Garibay, Helle Woeldike, Xujia Zhang, Henning Thoegersen, Peter Kresten Nielsen, Birgitte Andersen, Jishu Wang, Kristian Sass Bak-Jensen, Tina Moeller Tagmose
  • N-TERMINAL MODIFIED FGF21 COMPOUNDS
    Publication number: 20130190232
    Abstract: Analogues of FGF21 carrying a modifying, substituted ethylene or benzyl group can be used for treatment or prevention of diabetes, dyslipidemia, obesity, cardiovascular diseases, metabolic syndrome, and/or Non Alcoholic Fatty Liver Disease (NAFLD).
    Type: Application
    Filed: July 18, 2011
    Publication date: July 25, 2013
    Applicant: NOVO NORDISK A/S
    Inventors: Tina Moeller Tagmose, Patrick William Garibay, Xujia Zhang, Henning Thoegersen, Peter Kresten Nielsen, Birgitte Andersen, Jishu Wang, Kristian Sass Bak-Jensen, Helle Fabricius Woeldike
  • Insulin derivatives
    Patent number: 8476228
    Abstract: The present invention relates to insulin derivatives having a side chain attached either to the ?-amino group of the N-terminal amino acid residue of the B chain or to the ?-amino group of a Lys residue present in the B chain of the parent insulin via an amide bond which side chain comprises at least one aromatic group; at least one free carboxylic acid group or a group which is negatively charged at neutral pH, a fatty acid moiety with 4 to 22 carbon atoms in the carbon chain; and possible linkers which link the individual components in the side chain together via amide bonds.
    Type: Grant
    Filed: October 14, 2011
    Date of Patent: July 2, 2013
    Assignee: Novo Nordisk A/S
    Inventors: János Tibor Kodra, Patrick William Garibay, Thomas Hoeg-Jensen, Ib Jonassen, Peter Madsen, Tina Møller Tagmose
  • Protease Stabilized, Pegylated Insulin Analogues
    Publication number: 20120071402
    Abstract: Novel PEGylated insulin analogues exhibiting resistance towards proteases can, effectively, be administered pulmonary or orally. The insulin analogues contain B25H and A14E or A14H. The PEGylation is at B29K.
    Type: Application
    Filed: November 29, 2011
    Publication date: March 22, 2012
    Applicant: Novo Nordisk A/S
    Inventors: Peter Madsen, Thomas Hoeg-Jensen, Thomas Børglum Kjeldsen, Tina Møller Tagmose
  • Insulin derivatives
    Publication number: 20120035104
    Abstract: The present invention relates to insulin derivatives having a side chain attached either to the ?-amino group of the N-terminal amino acid residue of the B chain or to the ?-amino group of a Lys residue present in the B chain of the parent insulin via an amide bond which side chain comprises at least one aromatic group; at least one free carboxylic acid group or a group which is negatively charged at neutral pH, a fatty acid moiety with 4 to 22 carbon atoms in the carbon chain; and possible linkers which link the individual components in the side chain together via amide bonds.
    Type: Application
    Filed: October 14, 2011
    Publication date: February 9, 2012
    Applicant: Novo Nordisk A/S
    Inventors: Janos Tibor Kodra, Patrick William Garibay, Thomas Hoeg-Jensen, Ib Jonassen, Peter Madsen, Tina Moeller Tagmose
  • FGF21 ANALOGUES AND DERIVATIVES
    Publication number: 20120035099
    Abstract: Derivatives of Fibroblast Growth Factor 21 which have improved properties for treating diabetes can be prepared by a recombinant process.
    Type: Application
    Filed: June 6, 2011
    Publication date: February 9, 2012
    Applicant: NOVO NORDISK A/S
    Inventors: WILLIAM PATRICK GARIBAY, HELLE WÖLDIKE, XUJIA ZHANG, HENNING THØGERSEN, PETER KRESTEN NIELSEN, BIRGITTE ANDERSEN, JISHU WANG, KRISTIAN SASS BAK-JENSEN, TINA MØLLER TAGMOSE